Over the past few decades, cardiovascular disease and diabetes have emerged as major public health problems, both as distinct clinical entities and as comorbid conditions. As a result, the fields of vascular biology and endocrinology are working more closely now than ever before. With chapters by renowned experts, Cardiovascular Endocrinology: Shared Pathways and Clinical Crossroads emphasizes the considerable physiological interrelationships and clinical correlations between the specialties of cardiovascular medicine and endocrinology. Offering a wealth of information, Cardiovascular Endocrinology: Shared Pathways and Clinical Crossroads provides a range of insights, including a novel view of the hormonal regulation of the vascular system and the disruption of the nitric oxide signaling system. It also addresses the role of fatty acids and cytokines in the development of this problem. Importantly, this unique title also provides a state-of-the-art update on the importance of other hormones such as thyroid hormone and steroids, as well as the pathophysiology of cardiovascular disease and controversies surrounding the use of hormone replacement therapy. In all, Cardiovascular Endocrinology: Shared Pathways and Clinical Crossroads is a first-of-its-kind title that discusses and summarizes important clinical topics in cardiology and endocrinology. It offers clinicians and researchers an important resource for navigating the increasingly interrelated pathways of cardiovascular and endocrinologic disorders. The authors discuss a range of important issues from epidemiology to bench research to translation of this research to clinical practice.

Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine discusses the close intersection between metabolic disorders and cardiovascular disease, covering the basic science and pathophysiology of disease and the latest research in pharmacological approaches and translational therapeutic options. This book is a valuable resource for the vascular and endocrinology clinical and research communities in need of knowledge and potential outcomes. The global increase in the prevalence of cardiometabolic disorders, and the introduction of therapeutic options for treating metabolic disease that also lower cardiovascular risk, is bringing endocrinologists and cardiologists together in a shared clinical experience. - Discusses the intersection between metabolic disorders and cardiovascular diseases - Provides a comprehensive understanding of the relevant pathophysiology of diseases as a basis for the evidence-based management of cardiometabolic disorders - Offers a comprehensive reference, ranging from basic science and pathophysiology to clinical diagnostics and management

Blackwell Underground Clinical Vignettes: Internal Medicine I, Third Edition is your primary source for clinically relevant, case-based material essential for USMLE Step 2 review. Each Clinical Vignette simulates USMLE format, and includes classic buzzwords in history taking, physical examination, lab, imaging, and pathology. Internal Medicine I covers cardiology, endocrinology, gastroenterology, and hematology/oncology; another volume, Internal Medicine II, covers dermatology, infectious disease, nephrology, urology, pulmonary medicine, and rheumatology. Blackwell Underground Clinical Vignettes: Internal Medicine I, Third Edition is perfect for medical students. Physician assistants, nurse practitioners, and related health professionals will also find Underground Clinical Vignettes valuable.

Metabolic syndrome is a dangerous combination of cardiovascular risk factors that correlate with each other and can increase cardio and cerebrovascular events. The incidence of metabolic syndrome often parallels that of obesity and type 2 diabetes. It is widespread; in the United States, more than 40% of people over the age of 50 have metabolic syndrome. The diagnosis of metabolic syndrome is based on the coexistence of at least three risk factors including waist circumference greater than 102 cm in men or 88 cm in women, systolic blood pressure greater than 130 mmHg and diastolic greater than 85 mmHg, HDL cholesterol less than 40 mg/dl in men or 50 mg/dl in women, triglyceridemia higher than 150 mg/dl and finally fasting glycaemia higher than 110 mg/dl.

​This authoritative volume examines the major laws, regulations and guidelines related to pharmaceutical product development in China. With a focus on patent, clinical and registration strategies, the book helps Western companies introduce their clinical drugs to the Chinese market, determine a strategic path and bridge the gap for regulatory and legal differences between China and the Western world. For a better understanding of the drug registration process, it explores the differences between the China Food and Drug Administration (CFDA)—including its regulations and registration procedures—and those of the Western world. The volume discusses disparities between China's application requirements compared to Western standards to make it easier for companies to prepare their application packages. It also provides detailed commentary on CFDA guidelines in reference to clinical trial (IND) and market application (NDA) requirements. Overall, this book offers guidance for Western companies aspiring to expand into China’s pharmaceutical market in hopes that they may gain a fundamental understanding of its rules and complexities in order to ensure a smooth transition and prevent future issues.